

Special Issue

Prevention and Antibiotic Treatment of Periprosthetic Joint Infection

Message from the Guest Editors

PJI is a devastating complication after joint replacement. Different surgical treatments have been proposed, such as radical debridement and one- or two-stage or even resection arthroplasty with different antibiotic protocols (short duration, long duration, suppression treatment, etc.). Different alternatives have been suggested to be useful in decreasing infection risk after joint replacement, such as preoperative optimization, systemic antibiotics, antibiotic-loaded bone cement, local antibiotic carriers different from bone cement, antiseptic-coated sutures, or active postsurgical dressing, among others. The purpose of this Special Issue is share different options for PJI prophylactic and treatment as well as other pertinent information to readers to facilitate decisions regarding which options are better for their daily work.

Guest Editors

Dr. Pablo Sanz-Ruíz

Department of Traumatology and Orthopaedic Surgery, General University Hospital Gregorio Marañón, Madrid, Spain

Dr. Javier Vaquero

General University Gregorio Marañón Hospital, Madrid, Spain

Deadline for manuscript submissions

closed (31 October 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/149637

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)